Author Disambiguator

Group #1

Matched potential author: Asher A Chanan Khan - author of 18 items

Title	Authors (identified)	Published In	Identifier(s)	Topic	Published Date	Match?
Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?	[1]Sikander Ailawadhi, [2]Kirtipal Bhatia, [3]Sonikpreet Aulakh, [4]Zahara Meghji, [5]Asher Chanan-Khan [Full author list]	Current hematologic malignancy reports [missing]	DOI: 10.1007/S11899-017-0393-Y [ORCID] PubMed: 28626849 [ORCID]	multiple myeloma [missing]	2017-06-19	Asher A Chanan Khan (Q114300389; 18 items)
Preclinical models of Waldenström's macroglobulinemia and drug resistance	[1]Sikander Ailawadhi, [2]Aneel Paulus, [3]Asher Chanan-Khan [Full author list]	Best Practice and Research: Clinical Haematology [missing]	DOI: 10.1016/J.BEHA.2016.08.017 [ORCID] PubMed: 27825463 [ORCID]	Waldenström macroglobulinemia [missing]	2016-06-01
Novel therapeutic targets in Waldenstrom macroglobulinemia	[1]Aneel Paulus, [2]Sikander Ailawadhi, [3]Asher Chanan-Khan [Full author list]	Best Practice and Research: Clinical Haematology [missing]	DOI: 10.1016/J.BEHA.2016.08.020 [ORCID] PubMed: 27825468 [ORCID]		2016-06-01
Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis	[1]Sikander Ailawadhi, [2]Pooja Advani, [3]Dongyun Yang, [4]Radhika Ghosh, [5]Abhisek Swaika, [6]Vivek Roy, [7]James Foran, [8]Gerardo Colon-Otero, [9]Asher Chanan-Khan [Full author list]	Cancer [missing]	DOI: 10.1002/CNCR.29771 [ORCID] PubMed: 26565660 [ORCID]		2015-11-13
Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review	[1]Jennifer A Crozier, [2]Taimur Sher, [3]Dongyun Yang, [4]Abhisek Swaika, [5]James Foran, [6]Radhika Ghosh, [7]Han Tun, [8]Gerardo Colon-Otero, [9]Kevin Kelly, [10]Asher Chanan-Khan, [11]Sikander Ailawadhi [Full author list]	Clinical Lymphoma, Myeloma & Leukemia [missing]	DOI: 10.1016/J.CLML.2015.06.005 [ORCID] PubMed: 26198444 [ORCID]		2015-06-19
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma	[1]Miriam Y Kim, [2]Richard Sposto, [3]Abhisek Swaika, [4]Hitomi Asano, [5]Ahsan Alamgir, [6]Asher Chanan-Khan, [7]Sikander Ailawadhi [Full author list]	Oncology [missing]	DOI: 10.1159/000364880 [ORCID] PubMed: 25059308 [ORCID]		2014-07-18
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs	[1]Aneel Paulus, [2]Aisha Masood, [3]Kena C Miller, [4]A N M Nazmul H Khan, [5]Drusilla Akhtar, [6]Pooja Advani, [7]James Foran, [8]Candido Rivera, [9]Vivek Roy, [10]Gerardo Colon-Otero, [11]Kasyapa Chitta, [12]Asher Chanan-Khan [Full author list]	British Journal of Haematology [missing]	DOI: 10.1111/BJH.12731 [ORCID] PubMed: 24467634 [ORCID]	ixazomib [missing]	2014-01-27
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia	[1]Aneel Paulus, [2]Kasyapa Chitta, [3]Sharoon Akhtar, [4]David Personett, [5]Kena C Miller, [6]Kevin J Thompson, [7]Jennifer Carr, [8]Shaji K Kumar, [9]Vivek Roy, [10]Stephen M Ansell, [11]Joseph R Mikhael, [12]Angela Dispenzieri, [13]Craig B Reeder, [14]Candido E Rivera, [15]James Foran, [16]Asher Chanan-Khan [Full author list]	British Journal of Haematology [missing]	DOI: 10.1111/BJH.12633 [ORCID] PubMed: 24236538 [ORCID]	cytotoxicity [missing]; dexamethasone [missing]	2013-11-17	Asher A Chanan Khan (Q114300389; 18 items)
Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups	[1]Sikander Ailawadhi, [2]Ibrahim T Aldoss, [3]Dongyun Yang, [4]Pedram Razavi, [5]Wendy Cozen, [6]Taimur Sher, [7]Asher Chanan-Khan [Full author list]	British Journal of Haematology [missing]	DOI: 10.1111/J.1365-2141.2012.09124.X [ORCID] PubMed: 22533740 [ORCID]	multiple myeloma [missing]	2012-04-26	Asher A Chanan Khan (Q114300389; 18 items)
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma	[1]Sikander Ailawadhi, [2]Jeff Miecznikowski, [3]Dan P Gaile, [4]Dongliang Wang, [5]Taimur Sher, [6]George Mulligan, [7]Barb Bryant, [8]Gregory E Wilding, [9]Terry Mashtare, [10]Leighton Stein, [11]Aisha Masood, [12]Rachel Neuwirth, [13]Kelvin P Lee, [14]Asher Chanan-Khan [Full author list]	Leukemia & Lymphoma [missing]	DOI: 10.3109/10428194.2011.637212 [ORCID] PubMed: 22054286 [ORCID]	overexpression [missing]	2011-12-06
Targeted treatment for chronic lymphocytic leukemia	[1]Aisha Masood, [2]Taimur Sher, [3]Aneel Paulus, [4]Kena C Miller, [5]Kasyapa S Chitta, [6]Asher Chanan-Khan [Full author list]	OncoTargets and Therapy [missing]	DOI: 10.2147/OTT.S7173 [ORCID] PubMed: 22162923 [ORCID]	lymphocyte [missing]	2011-11-04
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients	[1]Taimur Sher, [2]Sikander Ailawadhi, [3]Kena C Miller, [4]Debbie Manfredi, [5]Margaret Wood, [6]Wei Tan, [7]Gregory Wilding, [8]Myron S Czuczman, [9]Francisco J Hernandez-Ilizaliturri, [10]Fredrick Hong, [11]Raman Sood, [12]Saif Soniwala, [13]William Lawrence, [14]Saad Jamshed, [15]Aisha Masood, [16]Daniel Iancu, [17]Kelvin Lee, [18]Asher Chanan-Khan [Full author list]	British Journal of Haematology [missing]	DOI: 10.1111/J.1365-2141.2011.08703.X [ORCID] PubMed: 21554260 [ORCID]	doxorubicin [missing]; thalidomide [missing]	2011-05-09	Asher A Chanan Khan (Q114300389; 18 items)
Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia	[1]Pooja P Advani, [2]Aneel Paulus, [3]Ayesha Masood, [4]Taimur Sher, [5]Asher Chanan-Khan [Full author list]	Expert Opinion on Drug Metabolism & Toxicology [missing]	DOI: 10.1517/17425255.2011.579105 [ORCID] PubMed: 21521129 [ORCID]	leukemia [missing]; pharmacokinetics [missing]; lymphocyte [missing]	2011-04-27
Plasma cell leukaemia and other aggressive plasma cell malignancies	[1]Taimur Sher, [2]Kena C Miller, [3]George Deeb, [4]Kelvin Lee, [5]Asher Chanan-Khan [Full author list]	British Journal of Haematology [missing]	DOI: 10.1111/J.1365-2141.2010.08157.X [ORCID] PubMed: 20701603 [ORCID]	leukemia [missing]	2010-08-01
Management of patients with chronic lymphocytic leukemia treated with lenalidomide	[1]Kena C Miller, [2]Laurie Musial, [3]Amy Whitworth, [4]Asher Chanan-Khan [Full author list]	Clinical Journal of Oncology Nursing [missing]	DOI: 10.1188/10.CJON.491-499 [ORCID] PubMed: 20682505 [ORCID]	leukemia [missing]; lymphocyte [missing]; chronic lymphocytic leukemia [missing]	2010-08-01
Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report	[1]Taimur Sher, [2]Kena C Miller, [3]Kelvin Lee, [4]Asher Chanan-Khan [Full author list]	Clinical Lymphoma and Myeloma [missing]	DOI: 10.3816/CLM.2009.N.065 [ORCID] PubMed: 19717386 [ORCID]		2009-08-01
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.	[1]Asher Chanan-Khan, [2]Kena C Miller, [3]Laurie Musial, [4]Swaminathan Padmanabhan, [5]Jihnhee Yu, [6]Sikander Ailawadhi, [7]Taimur Sher, [8]Alice Mohr, [9]Zale P Bernstein, [10]Maurice Barcos, [11]Mehul Patel, [12]Dan Iancu, [13]Kelvin Lee, [14]Myron S Czuczman [Full author list]	Leukemia & Lymphoma [missing]	DOI: 10.1080/10428190902912460 [ORCID] PubMed: 19479618 [ORCID]	doxorubicin [missing]; thalidomide [missing]; phase II clinical trial [missing]	2009-07-01
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).	[1]Asher Chanan-Khan, [2]Kena C Miller, [3]Kenichi Takeshita, [4]Alexandra Koryzna, [5]Kathleen Donohue, [6]Zale P Bernstein, [7]Alice Mohr, [8]Donald Klippenstein, [9]Paul Wallace, [10]Jerome B Zeldis, [11]Christine Berger, [12]Myron S Czuczman [Full author list]	Blood [missing]	DOI: 10.1182/BLOOD-2005-02-0669 [ORCID] PubMed: 16051743 [ORCID]	leukemia [missing]; thalidomide [missing]; lymphocyte [missing]; chronic lymphocytic leukemia [missing]; phase I clinical trial [missing]	2005-07-28
Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma	[1]Asher Chanan-Khan, [2]Kena C Miller [Full author list]	Leukemia & Lymphoma [missing]	DOI: 10.1080/10428190500097086 [ORCID] PubMed: 16019567 [ORCID]	doxorubicin [missing]; thalidomide [missing]	2005-07-01
Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab	[1]Jeyanthi Ramanarayanan, [2]Francisco J Hernandez-Ilizaliturri, [3]Asher Chanan-Khan, [4]Myron S Czuczman [Full author list]	British Journal of Haematology [missing]	DOI: 10.1111/J.1365-2141.2004.05239.X [ORCID] PubMed: 15566355 [ORCID]	apoptotic process [missing]	2004-12-01
A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma	[1]Zale P Bernstein, [2]Asher Chanan-Khan, [3]Kena C Miller, [4]Donald W Northfelt, [5]Gabriel Lopez-Berestein, [6]Parkash S Gill [Full author list]	Cancer [missing]	DOI: 10.1002/CNCR.11009 [ORCID] PubMed: 12467070 [ORCID]	tretinoin [missing]	2002-12-01

Group #2

Matched potential author: Asher A Chanan Khan - author of 18 items

Check all | Uncheck all

Title	Authors (identified)	Published In	Identifier(s)	Topic	Published Date	Match?
Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15	[1]Xin Wang, [2]Pádraig D'Arcy, [3]Thomas R Caulfield, [4]Aneel Paulus, [5]Kasyapa Chitta, [6]Chitralekha Mohanty, [7]Joachim Gullbo, [8]Asher Chanan-Khan, [9]Stig Linder [Full author list]	Chemical Biology and Drug Design [missing]	DOI: 10.1111/CBDD.12571 [ORCID] PubMed: 25854145 [ORCID]		2015-11-01
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells	[1]Kasyapa Chitta, [2]Aneel Paulus, [3]Sharoon Akhtar, [4]Maja Kristin K Blake, [5]Thomas R Caulfield, [6]Anne J Novak, [7]Stephen M Ansell, [8]Pooja Advani, [9]Sikander Ailawadhi, [10]Taimur Sher, [11]Stig Linder, [12]Asher Chanan-Khan [Full author list]	British Journal of Haematology [missing]	DOI: 10.1111/BJH.13304 [ORCID] PubMed: 25691154 [ORCID]	apoptotic process [missing]	2015-02-17	Asher A Chanan Khan (Q114300389; 18 items)

Group #3

Check all | Uncheck all

Title	Authors (identified)	Published In	Identifier(s)	Topic	Published Date
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial	[1]Clemens M Wendtner, [2]Michael Hallek, [3]Graeme A M Fraser, [4]Anne-Sophie Michallet, [5]Peter Hillmen, [6]Jan Dürig, [7]Matt Kalaycio, [8]John G Gribben, [9]Stephan Stilgenbauer, [10]Andreas Buhler, [11]Thomas J Kipps, [12]Brendan Purse, [13]Jennie Zhang, [14]Sabine De Bedout, [15]Jay Mei, [16]Asher Chanan-Khan [Full author list]	Leukemia & Lymphoma [missing]	DOI: 10.3109/10428194.2015.1128540 [ORCID] PubMed: 26763349 [ORCID]	leukemia [missing]; lymphocyte [missing]; chronic lymphocytic leukemia [missing]; multicenter clinical trial [missing]; phase II clinical trial [missing]	2016-01-14
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study	[1]Asher Chanan-Khan, [2]Paula Cramer, [3]Fatih Demirkan, [4]Graeme Fraser, [5]Rodrigo Santucci Silva, [6]Sebastian Grosicki, [7]Aleksander Pristupa, [8]Ann Janssens, [9]Jiri Mayer, [10]Nancy L Bartlett, ..., [11-Q41104793]Leylagul Kaynar, ... [Full author list]	Lancet Oncology Commission [missing]	DOI: 10.1016/S1470-2045(15)00465-9 [ORCID] PubMed: 26655421 [ORCID]	leukemia [missing]; placebo [missing]; rituximab [missing]; bendamustine [missing]; lymphocyte [missing]; chronic lymphocytic leukemia [missing]; ibrutinib [missing]	2015-12-04
Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events	[1]Asher Chanan-Khan, [2]Thomas Kipps, [3]Stephan Stilgenbauer [Full author list]	Clinical advances in hematology & oncology : H & O [missing]	PubMed: 21192630 [ORCID]		2010-08-01

Group #4

Check all | Uncheck all

Title	Authors (identified)	Published In	Identifier(s)	Topic	Published Date	Match?
Cancer- and chemotherapy-induced anemia.	[1]George M Rodgers, [2]Pamela Sue Becker, [3]Charles L Bennett, [4]David Cella, [5]Asher Chanan-Khan, [6]Carolyn Chesney, [7]Charles S Cleeland, [8]Peter F Coccia, [9]Benjamin Djulbegovic, [10]Jennifer L Garst, ... [Full author list]	Journal of the National Comprehensive Cancer Network [missing]	DOI: 10.6004/JNCCN.2008.0042 [ORCID] PubMed: 18597709 [ORCID]	chemotherapy [missing]	2008-07-01
Cancer- and treatment-related anemia	[1]George M Rodgers, [2]David Cella, [3]Asher Chanan-Khan, [4]Carolyn Chesney, [5]Charles S Cleeland, [6]Peter F Coccia, [7]George D Demetri, [8]Benjamin Djulbegovic, [9]Jennifer L Garst, [10]Margaret Gore, [11]Eric H Kraut, [12]Weei-Chin Lin, [13]Michael Millenson, [14]Victoria Mock, [15]Denise Reinke, [16]Joseph Rosenthal, [17]Paul Sabbatini [Full author list]	Journal of the National Comprehensive Cancer Network [missing]	DOI: 10.6004/JNCCN.2005.0046 [ORCID] PubMed: 16316613 [ORCID]		2005-11-01

Group #5

Check all | Uncheck all

Title	Authors (identified)	Published In	Identifier(s)	Topic	Published Date	Match?
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice	[1]Heidi D Finnes, [2]Kari G Rabe, [3]Timothy G. Call, [4]Wei Ding, [5]Saad S. Kenderian, [6]Deborah A Bowen, [7]Michael Conte, [8]Kristen B McCullough, [9]Julianna A Merten, [10]Gabriel T Bartoo, [11]Matthew D Smith, [12]Jose Leis, [13]Asher Chanan-Khan, [14]Susan M. Schwager, [15]Susan L Slager, [16]Neil E Kay, [17]Tait D Shanafelt, [18]Sameer A Parikh [Full author list]	Leukemia & Lymphoma [missing]	DOI: 10.1080/10428194.2016.1251592 [ORCID] PubMed: 27820970 [ORCID]	leukemia [missing]; lymphocyte [missing]; chronic lymphocytic leukemia [missing]; ibrutinib [missing]	2016-11-08
The efficacy of ibrutinib in the treatment of Richter syndrome	[1]Mazie Tsang, [2]Tait D Shanafelt, [3]Timothy G. Call, [4]Wei Ding, [5]Asher Chanan-Khan, [6]Jose F Leis, [7]Grzegorz S Nowakowski, [8]Deborah J. Bowen, [9]Michael Conte, [10]Susan M. Schwager, [11]Susan L Slager, [12]Neil E Kay, [13]Curtis A Hanson, [14]Sameer A Parikh [Full author list]	Blood [missing]	DOI: 10.1182/BLOOD-2014-12-610782 [ORCID] PubMed: 25745187 [ORCID]	ibrutinib [missing]	2015-03-01

Group #6

Check all | Uncheck all

Title	Authors (identified)	Published In	Identifier(s)	Topic	Published Date	Match?
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study	[1]Asher Chanan-Khan, [2]Kena C Miller, [3]Laurie Musial, [4]David Lawrence, [5]Swaminathan Padmanabhan, [6]Kenichi Takeshita, [7]Carl W Porter, [8]David W Goodrich, [9]Zale P Bernstein, [10]Paul Wallace, [11]David Spaner, [12]Alice Mohr, [13]Catriona Byrne, [14]Francisco Hernandez-Ilizaliturri, [15]Cynthia Chrystal, [16]Petr Starostik, [17]Myron S Czuczman [Full author list]	Journal of Clinical Oncology [missing]	DOI: 10.1200/JCO.2005.05.0401 [ORCID] PubMed: 17088571 [ORCID]	leukemia [missing]; lymphocyte [missing]; chronic lymphocytic leukemia [missing]	2006-11-06
Immunomodulating drugs for chronic lymphocytic leukaemia	[1]Asher Chanan-Khan, [2]Carl W Porter [Full author list]	Lancet Oncology Commission [missing]	DOI: 10.1016/S1470-2045(06)70723-9 [ORCID] PubMed: 16750498 [ORCID]	leukemia [missing]; lymphocyte [missing]	2006-06-01

Misc

Matched potential author: Asher A Chanan Khan - author of 18 items

Check all | Uncheck all

Title	Authors (identified)	Published In	Identifier(s)	Topic	Published Date	Match?
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery	[1]Alan H. Bryce, [2]Jan B Egan, [3]Mitesh J Borad, [4]A Keith Stewart, [5]Grzegorz S Nowakowski, [6]Asher Chanan-Khan, [7]Mrinal M Patnaik, [8]Stephen M Ansell, [9]Michaela S Banck, [10]Steven I Robinson, ... [Full author list]	Oncotarget [missing]	DOI: 10.18632/ONCOTARGET.16057 [ORCID] PubMed: 28423702 [ORCID]	genomics [missing]; data sharing [missing]	2017-04-01
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study	[1]Richard R Furman, [2]Herbert A Eradat, [3]Christine G DiRienzo, [4]Craig C Hofmeister, [5]Suzanne R Hayman, [6]John P Leonard, [7]Morton Coleman, [8]Ranjana H. Advani, [9]Asher Chanan-Khan, [10]Julie Switzky, [11]Qiming M Liao, [12]Damini Shah, [13]Roxanne C Jewell, [14]Steen Lisby, [15]Thomas S Lin [Full author list]	The Lancet. Haematology. [missing]	DOI: 10.1016/S2352-3026(16)30166-1 [ORCID] PubMed: 27914971 [ORCID]		2016-11-30	Asher A Chanan Khan (Q114300389; 18 items)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma	[1]Antonio Palumbo, [2]Asher Chanan-Khan, [3]Katja Weisel, [4]Ajay K Nooka, [5]Tamás Masszi, [6]Meral Beksac, [7]Ivan Špička, [8]Vania Hungria, [9]Markus Munder, [10]Maria V Mateos, [11]Tomer M Mark, [12]Ming Qi, [13]Jordan Schecter, [14]Himal Amin, [15]Xiang Qin, [16]William Deraedt, [17]Tahamtan Ahmadi, [18]Andrew Spencer, [19]Pieter Sonneveld, [20]CASTOR Investigators [Full author list]	The New England Journal of Medicine [missing]	DOI: 10.1056/NEJMOA1606038 [ORCID] PubMed: 27557302 [ORCID]	dexamethasone [missing]; multiple myeloma [missing]	2016-08-01	Asher A Chanan Khan (Q114300389; 18 items)
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma	[1]David S Siegel, [2]Thomas Martin, [3]Michael Wang, [4]Ravi Vij, [5]Andrzej Jakubowiak, [6]Sagar Lonial, [7]Suzanne Trudel, [8]Vishal Kukreti, [9]Nizar Bahlis, [10]Melissa Alsina, [11]Asher Chanan-Khan, [12]Francis K Buadi, [13]Frederic J Reu, ... [Full author list]	Blood [missing]	DOI: 10.1182/BLOOD-2012-05-425934 [ORCID] PubMed: 22833546 [ORCID]	multiple myeloma [missing]	2012-07-25	Asher A Chanan Khan (Q114300389; 18 items)
The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation	[1]Jennifer Blickwedehl, [2]Scott H Olejniczak, [3]Ryan Cummings, [4]Nilofar Sarvaiya, [5]Ana Mantilla, [6]Asher Chanan-Khan, [7]Tej K Pandita, [8]Marion Schmidt, [9]Craig B. Thompson, [10]Naveen Bangia [Full author list]	Molecular Cancer Research [missing]	DOI: 10.1158/1541-7786.MCR-11-0493-T [ORCID] PubMed: 22550082 [ORCID]		2012-05-01
CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment	[1]Jayakumar R Nair, [2]Louise M Carlson, [3]Chandana Koorella, [4]Cheryl H Rozanski, [5]Gerald E Byrne, [6]P Leif Bergsagel, [7]John P Shaughnessy, [8]Lawrence H Boise, [9]Asher Chanan-Khan, [10]Kelvin P Lee [Full author list]	Journal of Immunology [missing]	DOI: 10.4049/JIMMUNOL.1100016 [ORCID] PubMed: 21715687 [ORCID]		2011-06-29
Antitumor cytotoxic T-cell response induced by a survivin peptide mimic	[1]Michael J Ciesielski, [2]Manmeet S Ahluwalia, [3]Stephan A Munich, [4]Molly Orton, [5]Tara Barone, [6]Asher Chanan-Khan, [7]Robert A Fenstermaker [Full author list]	Cancer Immunology, Immunotherapy [missing]	DOI: 10.1007/S00262-010-0845-X [ORCID] PubMed: 20422411 [ORCID]	cytotoxicity [missing]	2010-04-27
Review: erythroleukemia: clinical course and management	[1]Aisha Masood, [2]Beata Holkova, [3]Asher Chanan-Khan [Full author list]	Clinical advances in hematology & oncology : H & O [missing]	PubMed: 20505652 [ORCID]	acute erythroid leukemia [missing]	2010-04-01
Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage.	[1]Nishitha Reddy, [2]Ioannis Karampelas, [3]Asher Chanan-Khan, [4]Robert Fenstermaker, [5]Swami Padmanabhan [Full author list]	Leukemia & Lymphoma [missing]	DOI: 10.1080/10428190701272371 [ORCID] PubMed: 17577791 [ORCID]		2007-06-01
Regular analgesic use and risk of multiple myeloma	[1]Kirsten Moysich, [2]Mathew R Bonner, [3]Gregory P Beehler, [4]James R Marshall, [5]Ravi J Menezes, [6]Julie A Baker, [7]Joli R Weiss, [8]Asher Chanan-Khan [Full author list]	Leukemia Research [missing]	DOI: 10.1016/J.LEUKRES.2006.07.027 [ORCID] PubMed: 16962170 [ORCID]	multiple myeloma [missing]	2007-04-01
Supportive care in multiple myeloma	[1]Asher Chanan-Khan, [2]Kena C Miller [Full author list]	Clinical Lymphoma and Myeloma [missing]	DOI: 10.3816/CLM.2006.N.038 [ORCID] PubMed: 16879769 [ORCID]		2006-07-01
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide	[1]Owen A O'Connor, [2]Emily A Smith, [3]Lorraine E Toner, [4]Julie Teruya-Feldstein, [5]Stanley Frankel, [6]Mark Rolfe, [7]Xiaohui Wei, [8]Shujun Liu, [10]Kenneth K Chan, [11]Asher Chanan-Khan, [4-Q28219585]Julie Teruya-Feldstein, [9]Guido Marcucci [Full author list]	Clinical Cancer Research [missing]	DOI: 10.1158/1078-0432.CCR-05-0308 [ORCID] PubMed: 16675587 [ORCID]		2006-05-01
Arterial thrombosis in four patients treated with thalidomide	[1]Sarah L Scarpace, [2]Theresa Hahn, [3]Hilary Roy, [4]Karen Brown, [5]Pamela Paplham, [6]Asher Chanan-Khan, [7]Koen van Besien, [8]Philip L McCarthy [Full author list]	Leukemia & Lymphoma [missing]	DOI: 10.1080/10428190400015675 [ORCID] PubMed: 15621807 [ORCID]	thalidomide [missing]; thrombosis [missing]	2005-02-01
Bcl-2 antisense therapy in B-cell malignancies	[1]Asher Chanan-Khan [Full author list]	Blood Reviews [missing]	DOI: 10.1016/J.BLRE.2004.11.002 [ORCID] PubMed: 15784299 [ORCID]		2005-01-05
Bcl-2 antisense therapy in hematologic malignancies	[1]Asher Chanan-Khan [Full author list]	Current Opinion in Oncology [missing]	DOI: 10.1097/01.CCO.0000142074.67968.EB [ORCID] PubMed: 15627020 [ORCID]		2004-11-01
Bcl-2 antisense therapy in B-cell malignant proliferative disorders	[1]Asher Chanan-Khan, [2]Myron S Czuczman [Full author list]	Current Treatment Options in Oncology [missing]	DOI: 10.1007/S11864-004-0017-3 [ORCID] PubMed: 15233903 [ORCID]		2004-08-01
Prevention and management of cardiotoxicity from antineoplastic therapy	[1]Asher Chanan-Khan, [2]Sridhar Srinivasan, [3]Myron S Czuczman [Full author list]	The Journal of Supportive Oncology [missing]	PubMed: 15328825 [ORCID]		2004-05-01
Radioimmunotherapy in non-Hodgkin lymphoma	[1]Asher Chanan-Khan, [2]Myron S Czuczman [Full author list]	Current Opinion in Oncology [missing]	DOI: 10.1097/00001622-200209000-00003 [ORCID] PubMed: 12192266 [ORCID]		2002-09-01

	Name	Description	Authored items	Identifiers	Employer(s)
	Asher A Chanan Khan	researcher	18
		Other Q number of this author

Potential publications

Group #1

Group #2

Group #3

Group #4

Group #5

Group #6

Misc

Potential author items

New Author Item

Author items in these papers

Common author name strings in these papers

Publishing venues for these papers

Topics for these papers